Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman
21.11.2019 21:02:00 EET | Business Wire | Press release
Carbon (www.carbon3d.com), the world’s leading digital manufacturing platform, announced today that Ellen J. Kullman, former Chairman and CEO of DuPont, has been named President and CEO of the company and Dr. Joseph M. DeSimone has been named Executive Chairman of the Board, effective immediately. Kullman will also remain on Carbon’s board of directors where she has served since 2016. Today’s leadership announcements are the result of a succession plan that DeSimone, Kullman, and members of the board have worked on to prepare the company for its next chapter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005835/en/
Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman (Photo: Business Wire)
Carbon has been strengthening its leadership bench over the past several months to support the growth of the business. As President and CEO, Kullman will lead the development and execution of short- and long-term strategies, positioning Carbon to continue delivering value to its employees, customers, partners, and shareholders around the world. DeSimone is transitioning into the role of Executive Chairman to focus on growing mainstream adoption of the Carbon Digital Manufacturing Platform and evangelizing the company’s vision to existing and prospective customers, partners, and the public.
“Today’s announcement is a great honor,” said Kullman. “I am privileged to have spent the last few years on the Carbon board working alongside Joe, one of the greatest entrepreneurs and scientists of our time. Joe has built Carbon into the world’s leading digital manufacturing platform, and as President and CEO of Carbon, I am excited to partner with Joe and build on the solid foundations he’s put into place.”
“For the last six years, I have led Carbon as Chief Executive Officer and am enormously proud of what we’ve accomplished during my tenure,” said DeSimone. “I know what we will accomplish under Ellen will be even more extraordinary. Ellen is the right person to lead Carbon today. She has broad experience across multiple businesses, cycles, and geographies. Her vision, outstanding leadership traits, and distinguished track record will continue to drive Carbon’s growth into the future. In assuming the Executive Chairman role, I will be able to focus on evangelizing the platform and driving adoption more widely.”
Prior to joining DuPont in 1988, Kullman worked for Westinghouse and General Electric. DuPont's board of directors elected Kullman President and a director of the company in October 2008 and Chief Executive Officer in January 2009. She was the nineteenth executive and the first woman to lead the company in its 212-year history. As a business leader, Kullman led double-digit growth of the company’s Safety and Protection business portfolio and started two successful high-growth businesses known today as DuPont Industrial Biosciences and DuPont Sustainable Solutions. During her seven years as CEO, Kullman led the company’s focus on growth in emerging international markets and championed the power of DuPont science and global market knowledge to transform industries. She executed a strong plan and decisively positioned the company for its next generation of growth.
Kullman is co-chair of the Paradigm for Parity coalition and a board director of United Technologies, Dell Technologies, Amgen, and Goldman Sachs. She is a member of the U.S. National Academy of Engineering and past president of the U.S. China Business Council. She serves on the board of trustees of Northwestern University. Kullman has been named one of the “50 Most Powerful Women in Business” by Fortune and one of the “World’s Most Powerful Women” by Forbes. She holds a B.S. in Mechanical Engineering from Tufts University and an MBA from the Kellogg School of Management of Northwestern University.
As co-founder of Carbon, DeSimone took on 3D printing by bringing together insights from diverse fields to co-invent the core technology that now drives the Carbon Platform. Powered by Digital Light Synthesis™ (DLS™) technology, the Carbon Platform is enabling companies to break free of traditional polymer manufacturing methods to advance product innovation. Just this week, he was recognized for his achievements by EY as the U.S. Entrepreneur of the Year.
Before founding Carbon in 2013, DeSimone was a professor at the University of North Carolina for over 20 years. DeSimone has made scientific breakthroughs in areas including green chemistry, medical devices, and nanotechnology, also co-founding several companies based on his research. At UNC, DeSimone built a strong culture in his research group centered on the notion that diversity is a fundamental tenet of innovation.
DeSimone has achieved international recognition as a scientist, inventor, and entrepreneur, earning major accolades including the U.S. Presidential Green Chemistry Challenge Award and the Lemelson-MIT Prize. In 2016, President Obama awarded DeSimone the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. He is also one of only roughly 20 individuals elected to all three U.S. National Academies—the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering.
About Carbon
Carbon’s mission is to reinvent how polymer products are designed, engineered, manufactured, and delivered towards a digital and sustainable future. Based in Silicon Valley, Carbon brings together innovations in software, hardware, and material science to deliver industry-leading digital manufacturing solutions. With Carbon’s ground-breaking Digital Light Synthesis™ technology and broad family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and time to market. To learn more, visit www.Carbon3d.com, like the Carbon Facebook page, or follow Carbon on Instagram and Twitter at @Carbon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005835/en/
Contact information
Iska Hain Saric, Head of Strategic Communications, pr@carbon3d.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom